+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 435 Actively Recruiting clinical trials

O

Actively Recruiting

Chronic hepatitis B virus HBV infection is a major global health issue that can lead to serious liver problems such as cirrhosis, liver cancer, and death. This observational study aims to gather detailed information from a broad group of Chinese patients with chronic HBV infection to better understand the factors that influence disease outcomes. The study involves creating a comprehensive database of clinical, epidemiological, biological, virological, immunologic, and treatment-related data from patients with chronic HBV infection. There are no drug interventions instead, participants are monitored as part of this long-term cohort. Participants will be followed over many years, with researchers tracking outcomes like loss of hepatitis B antigens, development of cirrhosis, liver failure, liver cancer, and mortality. Regular assessments will collect relevant health information to help identify the factors linked to disease progression. The study is planned to continue until 2030, providing extensive long-term data on chronic HBV infection.

All AgesAll Genders
6 locations
P

Actively Recruiting

Researchers are studying 89Zr-TLX250, a diagnostic imaging agent, to detect clear cell renal cell carcinoma ccRCC in Chinese patients with indeterminate renal masses. This Phase 3, open-label, single-arm study aims to confirm the safety, tolerability, sensitivity, and specificity of 89Zr-TLX250 PETCT imaging. The study supports prior ZIRCON trial data and involves adult patients scheduled for partial or total nephrectomy as part of their standard care. Participants will receive a single intravenous dose of 37 MBq of 89Zr-TLX250 containing 10 mg of girentuximab. Imaging of the abdomen using PETCT will be performed 5 days post-administration, with possible whole-body imaging if widespread disease is suspected. Nephrectomy will occur any time after imaging but within 90 days. Histological analysis of tumor samples will confirm diagnosis. The study includes approximately seven visits over 4 to 6 months. Assessments include baseline exams, PETCT imaging, surgery, and follow-up visits. Imaging and histological data will be centrally analyzed to evaluate diagnostic accuracy. Safety and tolerability will be monitored throughout. The study is expected to last about 12 months with 4 months of follow-up per participant.

Age: 18Years +All GendersPhase 3
8 locations
P

Actively Recruiting

Researchers are evaluating TQB2934, a special antibody designed to target multiple myeloma, a cancer affecting plasma cells. This antibody binds to T cells and cancer cells to activate the immune system to attack the disease. The study is a Phase 1 clinical trial focusing on safety and the bodys handling of the drug in patients with malignant plasma cell tumors. The study involves giving TQB2934 as a subcutaneous injection at doses of 40mg or 60mg. Treatment cycles occur once weekly during the first three cycles, then every two weeks for cycles four to six. If patients achieve a partial remission or better after six cycles, dosing continues every four weeks. Each treatment cycle lasts 28 days. Participants will undergo various assessments including blood tests to measure drug levels and immune response over 120 hours after each dose. Researchers will monitor adverse events for up to 24 months and evaluate treatment responses such as remission rates and survival outcomes. The total study participation includes treatment and long-term safety follow-up lasting up to two years.

Age: 18Years - 75YearsAll GendersPhase 1
14 locations
P

Actively Recruiting

Researchers are studying relapsed or refractory multiple myeloma in adults who have already received treatment with lenalidomide and a proteasome inhibitor but whose disease has progressed. The study aims to evaluate the effects of adding SG301 injection to the standard treatment of pomalidomide and dexamethasone. This is a randomized, placebo-controlled, double-blind, multicenter phase III clinical trial. The study has two stages. Stage 1 is to find the right dose of SG301 combined with pomalidomide and dexamethasone. Stage 2 randomly assigns participants to receive either SG301 injection plus pomalidomide and dexamethasone or a placebo plus the same drugs. SG301 and its placebo are given by intravenous infusion weekly for 8 weeks, then every 2 weeks. Pomalidomide capsules are taken orally once daily on days 1 to 21 of each 28-day cycle. Dexamethasone is taken orally or by infusion on days 1, 8, 15, and 22, with dose adjusted for low body weight. Participants continue treatment until their disease progresses, unacceptable side effects occur, or other stopping criteria are met. Researchers will monitor side effects, drug levels in the body, immune response, and treatment effects including progression-free survival and overall survival for up to about 4 years. The study includes regular assessments every 4 weeks initially, then every 8 weeks, with safety followed for about 30 days after treatment ends.

Age: 18Years - 75YearsAll GendersPhase 3
12 locations
E

Actively Recruiting

Researchers are evaluating CT0596, a chimeric antigen receptor T-cell CAR-T therapy, in patients with relapsed or refractory multiple myeloma RR MM who have already undergone multiple prior treatments. This Phase III, single-arm, open-label, multicenter clinical trial aims to study the safety, tolerability, effectiveness, how the cells behave in the body, and immune responses to CT0596 in these patients. The study uses a dose-escalation method in Phase I to find the best dose, then confirms the treatments effects in Phase II. Participants receive CT0596 CAR-T cells, with Phase I focusing on finding the maximum tolerated or recommended dose through a careful increase in dosage. Phase II evaluates the confirmed effective dose by measuring overall response rates at 12 weeks after infusion, using established response criteria. The study tracks outcomes over time up to 24 months, including safety events, response rates, disease progression, survival, and biological markers related to the therapy. During the trial, participants undergo multiple clinical visits for infusion and monitoring. Researchers assess side effects, treatment responses, blood markers, immune reactions, and disease status regularly up to two years after treatment. The trial includes evaluations by independent reviewers to confirm responses. Overall, participants are closely monitored for safety and treatment effects throughout the study period, which lasts until the study completion in 2031.

Age: 18Years +All GendersPhase 1Phase 2
2 locations
S

Actively Recruiting

Researchers are studying a treatment for elderly patients aged 65 and older with advanced triple-positive breast cancer. This cancer type is characterized by tumors that test positive for HER2, estrogen receptor, and progesterone receptor. The study aims to confirm the safety and effectiveness of a new combination therapy including Darcilide, pyrrotinib, and aromatase inhibitors letrozole, anastrozole, or exemestane for these patients who often have low physical status and poor tolerance for toxic chemotherapy. Participants will receive a combination treatment of Darcilide taken orally at 125 mg once daily for 21 days followed by 7 days off in 28-day cycles. They will also take an aromatase inhibitor daily and pyrrotinib starting at 240 mg orally once daily, with the dose potentially increasing to 320 mg if side effects are manageable. Treatment continues until disease progression, intolerable side effects, withdrawal of consent, or investigator decision. The study includes a screening period up to 28 days, followed by treatment and regular imaging assessments based on clinical routine and RECIST 1.1 criteria. During the study, participants will have safety checks, imaging evaluations, and follow-up visits including one 28 days after the last treatment. Safety follow-up continues until adverse events resolve or death. Efficacy follow-up continues until tumor progression, death, or consent withdrawal. Survival follow-up lasts until death, withdrawal, or the studys end date. Researchers will measure progression-free survival as the primary outcome over 29 months, along with overall survival, response rates, disease control, and duration of remission.

Age: 65Years +FEMALEPhase Not Applicable
1 location
P

Actively Recruiting

Researchers are conducting a Phase 1, open-label, multicenter clinical study to evaluate the safety, pharmacokinetics, and preliminary efficacy of HMPL-506 in patients with hematological malignancies. The study focuses on patients with specific genetic alterations in blood cancers, including relapsed or refractory Acute Myeloid Leukemia AML, Acute Lymphocytic Leukemia ALL, and multiple myeloma MM. The trial is sponsored by Hutchmed and aims to enroll between 60 and 132 patients across two phases dose escalation and dose expansion. In the dose escalation phase, approximately 30 to 38 patients with MLL-rearranged andor NPM1-mutant relapsedrefractory AML or ALL will receive escalating oral doses of HMPL-506 once daily. Starting at 50 mg, doses may increase based on safety, efficacy, and pharmacokinetic data, with adjustments guided by a Safety Monitoring Committee. The dose expansion phase will enroll about 30 to 60 patients divided into three cohorts based on specific genetic markers or disease type. Patients in this phase will receive the recommended phase 2 dose in 28-day cycles until disease progression, unacceptable toxicity, or other study endpoints. Participants will undergo regular assessments including bone marrow aspiration and biopsy, safety monitoring for dose-limiting toxicities and adverse events, and evaluations of anti-tumor efficacy every treatment cycle. Pharmacokinetic and pharmacodynamic analyses will be conducted, along with electrocardiograms and laboratory tests. Safety follow-up will continue up to 42 months after the last dose. The study includes monitoring for serious adverse events and overall survival, with participants remaining under medical supervision throughout the trial duration.

Age: 18Years +All GendersPhase 1
16 locations
L

Actively Recruiting

Researchers are studying the long-term safety and effectiveness of Inpegsomatropin Injection in children with Idiopathic Short Stature ISS who have completed previous Phase II clinical trials. This open-label, single-arm extension study allows participants and their guardians to decide on continued participation after a thorough evaluation of benefits and risks. The study is conducted at multiple centers and focuses on those who have already undergone initial treatment phases for ISS. Participants who qualify will receive weekly injections of Inpegsomatropin at a dose of 280 micrograms per kilogram under the skin. This treatment continues until the participant reaches near-adult height. After finishing the treatment period, participants enter a follow-up phase where their growth, development, medication use, and safety are monitored through outpatient visits. This process aims to gather detailed data on the long-term effects of the study drug. Throughout the study, participants will have regular assessments for safety, including monitoring of adverse events every 13 weeks during the first year and then yearly for up to 16 years. Researchers will also track changes in height, height velocity, bone age compared to chronological age, insulin-like growth factor-1 levels, and final height. The total participation period spans several years, allowing thorough observation of growth and development outcomes.

Age: 4Years - 13YearsAll GendersPhase Not Applicable
27 locations
S

Actively Recruiting

Researchers are evaluating the effectiveness and safety of Recombinant Botulinum Toxin Type A YY001 injections for treating upper limb spasticity in adults who have had a stroke. This randomized, double-blind, multi-center phase IIIII study compares YY001 with BOTOX4 and a placebo to better understand treatment options for this condition. Participants will receive a single intramuscular injection of either Recombinant Botulinum Toxin Type A YY001 with a dose of 200-400 units, BOTOX4 with a dose of 200 units, or a placebo prepared with saline. The study includes three groups the experimental group receiving YY001, an active-controlled group receiving BOTOX4, and a placebo-controlled group. Each participant receives only one injection during the treatment period. During the study, participants will be monitored at 1, 4, 8, and 12 weeks after treatment through assessments such as the Modified Ashworth Scale MAS for spasticity, Physicians Global Assessment, and Disability Assessment Scale DAS. Researchers will also track any adverse events and the presence of antibodies to the treatment. The primary outcome is the change in MAS score at week 4. The study lasts at least 12 weeks with ongoing safety and efficacy follow-up.

Age: 18Years - 75YearsAll GendersPhase 2Phase 3
24 locations
E

Actively Recruiting

Researchers are evaluating the effectiveness and safety of enicepatide, a dual GLP-1 and GIP receptor agonist, for weight management in adults with obesity or overweight who also have Type 2 diabetes mellitus T2DM. This phase III clinical trial compares multiple doses of enicepatide with a placebo to understand its impact on body weight and diabetes control. Participants will receive once-weekly injections of enicepatide or a placebo using an integrated drug-device combination product. The study has several dosing regimens for enicepatide and includes a placebo group for comparison. Treatment lasts up to 72 weeks, during which participants will receive their assigned injections regularly. Throughout the study, participants will be closely monitored with various assessments including body weight, hemoglobin A1c levels, waist circumference, fasting glucose and insulin levels, cholesterol levels, blood pressure, and quality of life measures. Safety evaluations will also be conducted to track adverse events. The study duration extends through week 72, with multiple outcome measures evaluated from baseline to the end of treatment.

Age: 18Years +All GendersPhase 3
210 locations

1-10 of 435

1